WallStreetZenWallStreetZen

NASDAQ: XBIO
Xenetic Biosciences Inc Stock

$0.71-0.02 (-2.74%)
Updated Feb 3, 2023
XBIO Price
$0.71
Fair Value Price
$1.67
Market Cap
$10.71M
52 Week Low
$0.24
52 Week High
$1.25
P/E
-1.38x
P/B
0.74x
P/S
4.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.55M
Earnings
-$6.91M
Gross Margin
100%
Operating Margin
-445.17%
Profit Margin
-445.2%
Debt to Equity
0.07
Operating Cash Flow
-$5M
Beta
0.72
Next Earnings
Apr 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A

XBIO Overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XBIO ($0.71) is undervalued by 57.81% relative to our estimate of its Fair Value price of $1.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XBIO ($0.71) is significantly undervalued by 57.81% relative to our estimate of its Fair Value price of $1.67 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XBIO due diligence checks available for Premium users.

Be the first to know about important XBIO news, forecast changes, insider trades & much more!

XBIO News

Valuation

XBIO fair value

Fair Value of XBIO stock based on Discounted Cash Flow (DCF)
Price
$0.71
Fair Value
$1.67
Undervalued by
57.57%
XBIO ($0.71) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XBIO ($0.71) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XBIO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.38x
Industry
10.7x
Market
15.09x

XBIO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
5.11x
XBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XBIO's financial health

Profit margin

Revenue
$414.3k
Net Income
-$804.0k
Profit Margin
-194.1%
XBIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$15.6M
Liabilities
$1.1M
Debt to equity
0.07
XBIO's short-term assets ($14.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIO's short-term assets ($14.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.1M
Investing
$0.0
Financing
$0.0
XBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XBIO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XBIO$10.71M-3.16%-1.38x0.74x
NEXI$10.80M-3.50%-0.16x0.23x
APVO$10.90M-2.73%1.70x0.69x
TRVN$10.98M-5.95%-0.17x0.50x
BLCM$11.03M+8.47%-5.33x1.47x

Xenetic Biosciences Stock FAQ

What is Xenetic Biosciences's quote symbol?

NASDAQ: XBIO) Xenetic Biosciences trades on the NASDAQ under the ticker symbol XBIO. Xenetic Biosciences stock quotes can also be displayed as NASDAQ: XBIO.

If you're new to stock investing, here's how to buy Xenetic Biosciences stock.

What is the 52 week high and low for Xenetic Biosciences (NASDAQ: XBIO)?

(NASDAQ: XBIO) Xenetic Biosciences's 52-week high was $1.25, and its 52-week low was $0.24. It is currently -43.52% from its 52-week high and 194.17% from its 52-week low.

How much is Xenetic Biosciences stock worth today?

(NASDAQ: XBIO) Xenetic Biosciences currently has 15,166,596 outstanding shares. With Xenetic Biosciences stock trading at $0.71 per share, the total value of Xenetic Biosciences stock (market capitalization) is $10.71M.

Xenetic Biosciences stock was originally listed at a price of $61.20 in Jun 30, 2016. If you had invested in Xenetic Biosciences stock at $61.20, your return over the last 6 years would have been -98.85%, for an annualized return of -52.47% (not including any dividends or dividend reinvestments).

How much is Xenetic Biosciences's stock price per share?

(NASDAQ: XBIO) Xenetic Biosciences stock price per share is $0.71 today (as of Feb 3, 2023).

What is Xenetic Biosciences's Market Cap?

(NASDAQ: XBIO) Xenetic Biosciences's market cap is $10.71M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xenetic Biosciences's market cap is calculated by multiplying XBIO's current stock price of $0.71 by XBIO's total outstanding shares of 15,166,596.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.